Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2026-08-25 16:06:37 ET · period of report 2026-08-21 · accession 0001327111-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-25 16:06 | 2026-08-21 | LYEL | Seely Lynn | Pres, CEO, Dir | S - Sale | $15.54 | -9,589 | 63.9K | -13% | -$149.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-21 | S | D | 9,589 | $15.54 | 63,899 | D | — | — | (F1) Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. |